INO inovio.com: Quick Liquidity Indicator

Inovio Pharmaceuticals (INO) is preparing to launch its first drug in the US by 2026, focusing on the fight against HPV. The business relies on a scalable DNA vaccine platform that enables the low-cost production of millions of doses and the licensing of developments. The current metric stands at 0.98. This price chart confirms the company's colossal potential as an immunotherapy leader investing in innovative CELLECTRA intradermal delivery systems.

INO: Inovio Pharmaceuticals, Inc. Quick Liquidity 07/04/2022 - 10/29/2026

inovio.com (INO) - metric breakdowns and financial figures

- share price and expert price forecast:

Stock Price Inovio Pharmaceuticals Inc|INO - Analyst Consensus Forecast

- company stock capitalization data:

Market Valuation Inovio Pharmaceuticals Inc|INO - Value Adjusted for Debt and Cash

- book capitalization indicators:

Accounting Value per Share Inovio|INO - Company Book Value|Market Capitalization to Book Value Ratio inovio.com|INO - Company Total Asset Base

- business debt structure and liquidity details:

- earnings and valuation multiples information:

INO - Company Profit

Initial company analysis:Inovio Pharmaceuticals

Manufactured product of Inovio Pharmaceuticals, Inc.

For the biotech sector, Inovio Pharmaceuticals (INO) relies critically on immediate liquidity due to the high costs of clinical trials. This metric assesses the ability to settle short-term debts using cash and accounts receivable, completely ignoring illiquid inventories. Analyzing the ratio of highly liquid assets to short-term liabilities allows for tracking the company's dependence on new equity offerings. A sufficient cash reserve minimizes bankruptcy risks in the event of delays in vaccine development.

Competitors of Inovio Pharmaceuticals (INO)